Cue Biopharma Statistics
Share Statistics
Cue Biopharma has 63.35M shares outstanding. The number of shares has increased by 8.19% in one year.
| Shares Outstanding | 63.35M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 62.90M |
| Failed to Deliver (FTD) Shares | 642 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 1.78M, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 1.78M |
| Short % of Shares Out | 2.81% |
| Short % of Float | 2.83% |
| Short Ratio (days to cover) | 1.54 |
Valuation Ratios
The PE ratio is -2.38 and the forward PE ratio is -2.93.
| PE Ratio | -2.38 |
| Forward PE | -2.93 |
| PS Ratio | 22 |
| Forward PS | 5.9 |
| PB Ratio | 3.26 |
| P/FCF Ratio | -3.02 |
| PEG Ratio | n/a |
Enterprise Valuation
Cue Biopharma Inc. has an Enterprise Value (EV) of 86.97M.
| EV / Earnings | -1.71 |
| EV / Sales | 15.84 |
| EV / EBITDA | -1.89 |
| EV / EBIT | -1.67 |
| EV / FCF | -2.18 |
Financial Position
The company has a current ratio of 3.01, with a Debt / Equity ratio of 0.22.
| Current Ratio | 3.01 |
| Quick Ratio | 3.01 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 18.04 |
| Cash Flow / Debt | -4.89 |
| Interest Coverage | -41.89 |
Financial Efficiency
Return on equity (ROE) is -1.37% and return on capital (ROIC) is -100.71%.
| Return on Equity (ROE) | -1.37% |
| Return on Assets (ROA) | -0.82% |
| Return on Capital (ROIC) | -100.71% |
| Revenue Per Employee | 103.58K |
| Profits Per Employee | -957.23K |
| Employee Count | 53 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.78% in the last 52 weeks. The beta is 1.8, so Cue Biopharma 's price volatility has been higher than the market average.
| Beta | 1.8 |
| 52-Week Price Change | -66.78% |
| 50-Day Moving Average | 1.33 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 36.33 |
| Average Volume (20 Days) | 785.07K |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $5.49M and earned -$50.73M in profits. Earnings per share was $-1.11.
| Revenue | 5.49M |
| Gross Profit | -32.61M |
| Operating Income | -52.15M |
| Net Income | -50.73M |
| EBITDA | -46.05M |
| EBIT | -52.15M |
| Earnings Per Share (EPS) | -1.11 |
Balance Sheet
The company has $48.51M in cash and $14.70M in debt, giving a net cash position of $33.82M.
| Cash & Cash Equivalents | 48.51M |
| Total Debt | 14.70M |
| Net Cash | 33.82M |
| Retained Earnings | -301.19M |
| Total Assets | 44.81M |
| Working Capital | 20.47M |
Cash Flow
In the last 12 months, operating cash flow was -$39.96M and capital expenditures $0, giving a free cash flow of -$39.96M.
| Operating Cash Flow | -39.96M |
| Capital Expenditures | 0 |
| Free Cash Flow | -39.96M |
| FCF Per Share | -0.87 |
Margins
Gross margin is -593.93%, with operating and profit margins of -949.89% and -924.1%.
| Gross Margin | -593.93% |
| Operating Margin | -949.89% |
| Pretax Margin | -924.1% |
| Profit Margin | -924.1% |
| EBITDA Margin | -838.83% |
| EBIT Margin | -949.89% |
| FCF Margin | -727.89% |
Dividends & Yields
CUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -118.09% |
| FCF Yield | -67.1% |
Analyst Forecast
The average price target for CUE is $4, which is 325.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 325.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -10.78 |
| Piotroski F-Score | 4 |